12/9/2011

The FDA authorized Antares Pharma's oxybutynin, a topical gel for overactive bladder, in 84-milligram strength. Antares partner Watson Pharmaceuticals expects to launch the treatment next year.

Full Story:
Reuters

Related Summaries